Select your country

Africa
Asia
Europe
Latin America
North America
Oceania

Multiple Sclerosis

Having spent over 20 years researching and developing solutions for advancing MS care, we aim to improve the lives of those living with MS.


Addressing Multiple Sclerosis

We aim to improve the lives of those living with MS, having spent over 20 years researching and developing solutions for advancing MS care.

More than 2.3 million people are affected by Multiple Sclerosis (MS) worldwide[1] with most people diagnosed between the ages of 20 and 40.[2] It occurs more than twice as often in women than men[2] and is the most common, non-traumatic, disabling neurological disease in young adults.[2] Relapsing remitting MS (RRMS) is the most common form of MS – around 85 percent of people with MS are diagnosed with this type.[3]

MS is an autoimmune, chronic and inflammatory condition that affects the central nervous system (CNS). It can be very difficult to diagnose as there is no single test and symptoms (including issues with seeing, walking and talking) differ considerably from one person to the other.[4]

There is currently no cure for MS. In fact, no-one knows exactly what causes it. It’s believed to be an autoimmune disease where the immune system begins to attack the protective coating on the axons of nerve cells (neurons) called myelin.[2] While scientists are striving to discover what triggers these attacks, most agree that genetics, gender and environmental factors all play their part.[5]

But over the years, some discoveries have helped make the condition more manageable. However, there is still a medical need for further development and progress.

 

 

[1]  MS International Federation. Atlas of MS. Available from: https://www.msif.org/about-us/advocacy/atlas/. Accessed May 12, 2017.

[2] National Institute of Neurology Disorders and Strokes. Multiple Sclerosis: Hope Through Research. Available from: https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Multiple-Sclerosis-Hope-Through-Research.
Accessed May 12, 2017.

[3] MS Society. Relapsing Remitting (RRMS). Available from: https://www.mssociety.org.uk/what-is-ms/types-of-ms/relapsing-remitting-rrms.
Accessed May 12, 2017.

[4] MS Society. Diagnosis. Available from: https://www.mssociety.org.uk/what-is-ms/information-about-ms/diagnosis.
Accessed May 12, 2017.

[5] MS Society. Causes of MS. Available from: https://www.mssociety.org.uk/what-is-ms/information-about-ms/causes.
Accessed May 12, 2017.

Healthcare disclaimer

This website is intended to provide information regarding the businesses of Merck KGaA, Darmstadt, Germany to international audiences. There may be differences to the version of this website that appears in the United States and Canada. For more specific information about the company's healthcare business in the United States and Canada, please visit our EMD Serono website.

Check out more information

Take me back

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement